| scholarly article | Q13442814 |
| P50 | author | Christine Mummery | Q28842449 |
| Thomas Mathivet | Q38800762 | ||
| Helen M. Arthur | Q39407032 | ||
| Catarina Freitas | Q55603248 | ||
| Franck Lebrin | Q58291003 | ||
| Anne Eichmann | Q87813494 | ||
| P2093 | author name string | Bruno Larrivée | |
| Stieneke van den Brink | |||
| Christiane Bréant | |||
| Jean-Léon Thomas | |||
| Repke J Snijder | |||
| Cornelis J J Westermann | |||
| Johannes J Mager | |||
| Sabrina Martin | |||
| Karine Raymond | |||
| Frans Disch | |||
| Samly Srun | |||
| P2860 | cites work | Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 | Q24317667 |
| Thalidomide is an inhibitor of angiogenesis | Q24563363 | ||
| Hereditary haemorrhagic telangiectasia: a clinical and scientific review | Q24600839 | ||
| Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation | Q24653215 | ||
| Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis | Q24681191 | ||
| Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse | Q28512852 | ||
| Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development | Q28585397 | ||
| A murine model of hereditary hemorrhagic telangiectasia | Q28592376 | ||
| Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis | Q29614939 | ||
| Pericyte Loss and Microaneurysm Formation in PDGF-B-Deficient Mice | Q29615196 | ||
| VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia | Q29617501 | ||
| Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy | Q34090428 | ||
| PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis | Q34335508 | ||
| Defective paracrine signalling by TGFbeta in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia | Q34368675 | ||
| Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. | Q34381015 | ||
| Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer | Q34530109 | ||
| Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding | Q34606176 | ||
| NG2 cells generate both oligodendrocytes and gray matter astrocytes. | Q34719495 | ||
| Thalidomide for treatment of severe intestinal bleeding | Q35596432 | ||
| Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall | Q35967045 | ||
| TGF-beta receptor function in the endothelium. | Q36017194 | ||
| Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells | Q36217700 | ||
| Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture | Q36220333 | ||
| Development of the retinal vasculature | Q36745434 | ||
| The thalidomide saga | Q36763353 | ||
| Building blood vessels--stem cell models in vascular biology | Q36834586 | ||
| Extracellular control of TGFbeta signalling in vascular development and disease | Q36951674 | ||
| Endoglin-mediated vascular remodeling: mechanisms underlying hereditary hemorrhagic telangiectasia | Q37060998 | ||
| Endothelial-mural cell signaling in vascular development and angiogenesis | Q37375745 | ||
| Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series | Q43281038 | ||
| Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease. | Q43878903 | ||
| Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia? | Q44088852 | ||
| Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality | Q44385668 | ||
| STI-571 inhibits in vitro angiogenesis. | Q44597666 | ||
| Integrins in the mouse myotome: developmental changes and differences between the epaxial and hypaxial lineage | Q45057948 | ||
| A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias | Q46909275 | ||
| Bevacizumab in hereditary hemorrhagic telangiectasia | Q47807119 | ||
| Vascular Endothelial Growth Factor Serum Levels Are Elevated in Patients with Hereditary Hemorrhagic Telangiectasia | Q57617756 | ||
| Vascular normalization in Rgs5-deficient tumours promotes immune destruction | Q58897988 | ||
| Skin microvascular adaptations during maturation and aging of hairless mice | Q73015165 | ||
| Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling | Q80778833 | ||
| Reduced endothelial secretion and plasma levels of transforming growth factor-beta1 in patients with hereditary hemorrhagic telangiectasia type 1 | Q81770866 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nosebleed | Q202013 |
| thalidomide | Q203174 | ||
| hereditary hemorrhagic telangiectasia | Q776881 | ||
| P304 | page(s) | 420-428 | |
| P577 | publication date | 2010-04-04 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia | |
| P478 | volume | 16 |
| Q33719706 | ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway. |
| Q49711115 | Advances in the Medical Management of Vascular Anomalies |
| Q37958949 | Angiogenesis regulation by TGFβ signalling: clues from an inherited vascular disease |
| Q38365380 | Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia |
| Q36132803 | Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. |
| Q35053397 | Arteriovenous malformation in the adult mouse brain resembling the human disease |
| Q38872877 | Bone Morphogenetic Proteins in Vascular Homeostasis and Disease |
| Q91672936 | Bone morphogenetic protein receptor signal transduction in human disease |
| Q33843008 | Brain arteriovenous malformation modeling, pathogenesis, and novel therapeutic targets |
| Q37897171 | Brain arteriovenous malformation pathogenesis: a response-to-injury paradigm |
| Q30542261 | CCM1-ICAP-1 complex controls β1 integrin-dependent endothelial contractility and fibronectin remodeling |
| Q36041205 | CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma. |
| Q30426853 | Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies |
| Q85522762 | Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and 'instruct' them with pattern-recognition and motility programs |
| Q37949813 | Cerebrovascular disorders: molecular insights and therapeutic opportunities |
| Q38855307 | ChIP-seq reveals cell type-specific binding patterns of BMP-specific Smads and a novel binding motif |
| Q35336067 | Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia |
| Q58802000 | Clinical features and treatment of hereditary hemorrhagic telangiectasia |
| Q92882879 | Constitutive Active Mutant TIE2 Induces Enlarged Vascular Lumen Formation with Loss of Apico-basal Polarity and Pericyte Recruitment |
| Q92387633 | Continuous endoglin (CD105) overexpression disrupts angiogenesis and facilitates tumor cell metastasis |
| Q41869709 | Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity |
| Q87593055 | Could Thalidomide Be a Treatment Option for Arteriovenous Malformations? |
| Q34784416 | Directional next-generation RNA sequencing and examination of premature termination codon mutations in endoglin/hereditary haemorrhagic telangiectasia |
| Q37978259 | Disruption of embryonic vascular development in predictive toxicology |
| Q47884791 | Dynamic Remodeling of Pericytes In Vivo Maintains Capillary Coverage in the Adult Mouse Brain. |
| Q64938597 | EGFL7 Mediates BMP9-Induced Sprouting Angiogenesis of Endothelial Cells Derived from Human Embryonic Stem Cells. |
| Q26752740 | Effective treatment of gastrointestinal bleeding with thalidomide--Chances and limitations |
| Q36821724 | Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study |
| Q47968783 | Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia |
| Q61805998 | Endoglin as an Adhesion Molecule in Mature and Progenitor Endothelial Cells: A Function Beyond TGF-β |
| Q38074721 | Endoglin for tumor imaging and targeted cancer therapy. |
| Q36395997 | Endoglin is required in Pax3-derived cells for embryonic blood vessel formation. |
| Q27326704 | Endoglin regulates mural cell adhesion in the circulatory system |
| Q39401943 | Endoglin-based biological therapy in the treatment of angiogenesis-dependent pathologies. |
| Q36825271 | Endoglin: a critical mediator of cardiovascular health |
| Q35181476 | Endothelial depletion of Acvrl1 in mice leads to arteriovenous malformations associated with reduced endoglin expression |
| Q27300866 | Endothelial expression of TGFβ type II receptor is required to maintain vascular integrity during postnatal development of the central nervous system |
| Q37671796 | Endothelial signaling and the molecular basis of arteriovenous malformation |
| Q28729080 | Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI |
| Q27317227 | Epistaxis in hereditary hemorrhagic telangiectasia: an evidence based review of surgical management |
| Q44800182 | Executive summary of the 11th HHT international scientific conference |
| Q34076803 | Fine mapping of the hereditary haemorrhagic telangiectasia (HHT)3 locus on chromosome 5 excludes VE-Cadherin-2, Sprouty4 and other interval genes |
| Q39184690 | Generation, expansion and functional analysis of endothelial cells and pericytes derived from human pluripotent stem cells |
| Q34024081 | Hereditary haemorrhagic telangiectasia: Pathophysiology, diagnosis and treatment |
| Q87049002 | Hereditary hemorrhagic telangiectasia |
| Q38008300 | Hereditary hemorrhagic telangiectasia-related epistaxis: innovations in understanding and management |
| Q28236856 | Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis |
| Q57163936 | Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective |
| Q37635681 | High-Output Heart Failure Contributing to Recurrent Epistaxis Kiesselbach Area Syndrome in a Patient With Hereditary Hemorrhagic Telangiectasia |
| Q38552986 | How to manage patients with hereditary haemorrhagic telangiectasia. |
| Q37428779 | In vitro self-assembly of human pericyte-supported endothelial microvessels in three-dimensional coculture: a simple model for interrogating endothelial-pericyte interactions. |
| Q54304957 | Increase of circulating endothelial cells in patients with Hereditary Hemorrhagic Telangiectasia. |
| Q47138798 | Inhibiting DPP4 in a mouse model of HHT1 results in a shift towards regenerative macrophages and reduces fibrosis after myocardial infarction |
| Q54314849 | Inhibition of endothelial Slit2/Robo1 signaling by thalidomide restrains angiogenesis by blocking the PI3K/Akt pathway. |
| Q58698138 | It Takes Two: Endothelial-Perivascular Cell Cross-Talk in Vascular Development and Disease |
| Q34583622 | Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia |
| Q37949945 | Long-term therapy with thalidomide in hereditary hemorrhagic telangiectasia: case report and literature review |
| Q50501209 | Management of severe epistaxis after Young's procedure: a case report. |
| Q29547314 | Molecular mechanisms and clinical applications of angiogenesis |
| Q53512519 | Molecular mechanisms underlying therapeutic potential of pericytes. |
| Q28084374 | Mononuclear cells and vascular repair in HHT |
| Q36433174 | Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia |
| Q38367817 | Mouse models of hereditary hemorrhagic telangiectasia: recent advances and future challenges |
| Q35070041 | Mycobacterium leprae-host-cell interactions and genetic determinants in leprosy: an overview |
| Q30829560 | Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia |
| Q30570375 | Netrin-4 promotes mural cell adhesion and recruitment to endothelial cells. |
| Q36122786 | Nonsteroidal anti-inflammatory drugs alter vasa recta diameter via pericytes |
| Q30471456 | Normalization of the vasculature for treatment of cancer and other diseases |
| Q43565795 | Novel treatments for epistaxis in hereditary hemorrhagic telangiectasia: a systematic review of the clinical experience with thalidomide |
| Q34388065 | Optimal management of hereditary hemorrhagic telangiectasia |
| Q47906624 | Overview of small bowel angioectasias: clinical presentation and treatment options. |
| Q89553438 | Pathogenesis of non-hereditary brain arteriovenous malformation and therapeutic implications |
| Q38844997 | Pathogenetic significance and possibility as a therapeutic target of platelet derived growth factor |
| Q64911541 | Pericyte Structural Remodeling in Cerebrovascular Health and Homeostasis. |
| Q59404600 | Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization |
| Q24600644 | Pericytes Control Key Neurovascular Functions and Neuronal Phenotype in the Adult Brain and during Brain Aging |
| Q38374758 | Pericytes as targets in hereditary hemorrhagic telangiectasia. |
| Q92421283 | Pericytes in Hereditary Hemorrhagic Telangiectasia |
| Q49544674 | Pericytes: The Role of Multipotent Stem Cells in Vascular Maintenance and Regenerative Medicine |
| Q36089579 | Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer |
| Q36409013 | ProNGF, a cytokine induced after myocardial infarction in humans, targets pericytes to promote microvascular damage and activation |
| Q36600412 | Reduced mural cell coverage and impaired vessel integrity after angiogenic stimulation in the Alk1-deficient brain |
| Q47215203 | Reductions in brain pericytes are associated with arteriovenous malformation vascular instability. |
| Q48129889 | Relationships between epistaxis, migraines, and triggers in hereditary hemorrhagic telangiectasia |
| Q92271765 | Risk factors for hemorrhage of brain arteriovenous malformation |
| Q61800397 | Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia |
| Q90017015 | Severe anemia caused by hereditary hemorrhagic telangiectasia in a patient with Sjögren's syndrome and primary biliary cirrhosis |
| Q39752032 | Signaling required for blood vessel maintenance: molecular basis and pathological manifestations |
| Q58703191 | Soluble endoglin regulates expression of angiogenesis-related proteins and induction of arteriovenous malformations in a mouse model of hereditary hemorrhagic telangiectasia |
| Q37870053 | Stem cell self-renewal: lessons from bone marrow, gut and iPS toward clinical applications |
| Q48191012 | Structural basis of thalidomide enantiomer binding to cereblon |
| Q38354161 | Successful management of chronic gastrointestinal hemorrhage using bevacizumab in the setting of hereditary hemorrhagic telangiectasia |
| Q35544360 | Successful treatment of bleeding gastro-intestinal angiodysplasia in hereditary haemorrhagic telangiectasia with thalidomide |
| Q87681974 | TGF-β Signaling in Control of Cardiovascular Function |
| Q37976673 | TGFβ signaling and cardiovascular diseases |
| Q42563157 | Taking thalidomide out of rehab |
| Q26783734 | Targeting BMP signalling in cardiovascular disease and anaemia |
| Q56962810 | Targeting pericytes for therapeutic approaches to neurological disorders |
| Q34660391 | Teratogenic effects of thalidomide: molecular mechanisms |
| Q36695896 | Thalidomide Effects in Patients with Hereditary Hemorrhagic Telangiectasia During Therapeutic Treatment and in Fli-EGFP Transgenic Zebrafish Model |
| Q57129133 | Thalidomide Embryopathy: An Enigmatic Challenge |
| Q51730951 | Thalidomide Reduces Hemorrhage of Brain Arteriovenous Malformations in a Mouse Model. |
| Q47096268 | Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy |
| Q39248001 | Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study |
| Q86942615 | Thalidomide for hereditary haemorrhagic telangiectasia |
| Q64240431 | Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life |
| Q44394274 | Thalidomide is not able to inhibit radiation-induced heart disease |
| Q46827127 | Thalidomide treatment prevents chronic graft rejection after aortic transplantation in rats - an experimental study. |
| Q28085087 | Thalidomide-induced teratogenesis: history and mechanisms |
| Q90398446 | The TGFβ Family in Human Placental Development at the Fetal-Maternal Interface |
| Q38417116 | The clinical implications of thalidomide in inflammatory bowel diseases. |
| Q26852369 | The pericyte: a forgotten cell type with important implications for Alzheimer's disease? |
| Q36612613 | The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development |
| Q39036151 | The role of endoglin in post-ischemic revascularization. |
| Q91326575 | The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review |
| Q38121762 | Therapeutic effects of thalidomide in hematologic disorders: a review |
| Q38085966 | Transforming growth factor β family members in regulation of vascular function: in the light of vascular conditional knockouts |
| Q35807250 | Treatment of Hepatic Epithelioid Hemangioendothelioma: Finding Uses for Thalidomide in a New Era of Medicine |
| Q34744824 | Treatment of pediatric refractory Crohn's disease with thalidomide |
| Q34726819 | Treatment of the skin manifestations of hereditary hemorrhagic telangiectasia with pulsed dye laser. |
| Q60363723 | Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension |
| Q49711122 | Vascular Anomalies Caused by Abnormal Signaling within Endothelial Cells: Targets for Novel Therapies |
| Q36304260 | Vascular Integrity in the Pathogenesis of Brain Arteriovenous Malformation |
| Q27025402 | Vascular anomalies: from genetics toward models for therapeutic trials |
| Q30469815 | Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. |
| Q34972793 | Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials |
| Q42769613 | What's new in dermatological treatments? |
| Q34871044 | Whole mount immunofluorescent staining of the neonatal mouse retina to investigate angiogenesis in vivo |
| Q37332808 | Woman presenting with chronic iron deficiency anemia associated with hereditary hemorrhagic telangiectasia: a case report |
Search more.